Navigation Links
At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya
Date:12/10/2013

EXTON, Pa., Dec. 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that neurologist-reported patient share for Biogen Idec's Tecfidera, the newest oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, has increased significantly to seven percent among DMT-treated relapsing-remitting MS (RR-MS) patients, compared with one and three months post-launch. At six months post-launch, Tecfidera's patient share already matches that of Novartis's Gilenya, the first oral DMT (which became commercially available three years ago) and surpasses that of Genzyme's Aubagio, the second oral DMT, which launched one year ago. This growth in Tecfidera's patient share is driven by significant growth in volume per prescriber, reflecting widening adoption within individual practices, as well as significant expansion of the prescriber base (80 percent of surveyed neurologists). Patient origination data show a trend towards fewer patients initiating Tecfidera therapy following a treatment gap of two or more months, suggesting that most patients warehoused in anticipation of Tecfidera's launch have already been switched to the therapy at six months post-launch.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published LaunchTrends: Tecfidera (Wave 3) US 2013 report finds that one-fifth of Tecfidera-treated patients have experienced flushing and/or gastrointestinal events according to prescribers, significantly fewer than three months ago. This decrease is likely the result of increased physician and patient experience with the product, allowing for better management of potential side effects. However, tolerability issues continue to be the m
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
3. New silk technology preserves heat-sensitive drugs for months without refrigeration
4. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
5. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
6. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
7. New technology delivers sustained release of drugs for up to 6 months
8. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
9. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
10. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
11. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... ,, PORTLAND, Ore. , June 15 ... the use of genomic data in clinical decision making—will be addressing ... in personalized treatments for cancer patients. , ... "If you were diagnosed with non ...
... and WALTHAM, Mass. , June 15, 2010 ... LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced results ... superiority of BYDUREON™ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes ... , , ...
... ... have entered into a research collaboration with the goal of bringing more relevant and ... ... -- Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with ...
Cached Biology Technology:Personalized Treatments for Cancer Are Revolutionizing Patient Care 2Personalized Treatments for Cancer Are Revolutionizing Patient Care 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 2DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 4DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 5DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 6DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 7DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 8DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 9Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 2Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 3
(Date:4/23/2014)... EMBO today announced Sophie Martin of the University ... EMBO Gold Medal. The award acknowledges her work to ... development of the cell. , Martin has been working ... in particular the way in which the spatial organization ... In the last 11 years, she has been using ...
(Date:4/23/2014)... Like many social mammals, ravens form different types of ... partners and they also form strict dominance relations. From ... is a key ability in daily social life ("knowing ... relationships group members have with each other sets the ... The results of this study have been published in ...
(Date:4/22/2014)... There are all sorts of signaling strategies in nature. ... tails; satin bowbirds build specialized stick structures, called bowers, ... European bitterling males show off bright nuptial coloration during ... to communicate with others. , ... profound fitness implications for individuals that are either signaling ...
Breaking Biology News(10 mins):EMBO Gold Medal 2014 awarded to Sophie Martin 2Ravens understand the relations among others 2Best practices in communication for the animal world 2Best practices in communication for the animal world 3
... shows that male rats prenatally exposed to low doses of ... prostate inflammation and to go through puberty later than non-exposed ... on atrazine, an herbicide predominantly used to control weeds and ... and its byproducts are known to be relatively persistent in ...
... desire to understand how breast cancer starts has seen ... today win one of three 2010 L,Oreal Australia For ... postdoctoral fellow in the institute,s Stem Cells and Cancer ... profile for her studies of how breast stem cells ...
... FL Nova Southeastern University (NSU) is using part of a ... the Gulf Oil Spill,s impact on the marine ecosystem, officials ... of several educational institutions in Florida selected to work on ... the Gulf,s ecosystem and marine life. The projects were selected ...
Cached Biology News:Atrazine causes prostate inflammation in male rats and delays puberty 2L'Oreal Fellowship winner seeks to understand breast cancer 2NSU scientists receive BP money to research oil spill's impact 2
... RNase ONE Ribonuclease is a 27kDa periplasmic ... degradation of RNA to cyclic nucleotide monophosphate ... degradation of these intermediates to 3-NMPs (1). ... few known RNases that can cleave a ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
Biology Products: